Progress in the development of vaccines for hepatitis C virus infection

Ghasemi, F. and Rostami, S. and Meshkat, Z. (2015) Progress in the development of vaccines for hepatitis C virus infection. World Journal of Gastroenterology, 21 (42). pp. 11984-12002.

[img] Text
WJG-21-11984.pdf

Download (1MB)

Abstract

The hepatitis C virus (HCV), first described in 1989, is now a leading cause of liver cirrhosis and hepatocellular carcinoma. With more than 170 million people infected globally, this virus is a major public health issue. The current standard therapy is based on interferon in combination with ribavirin. This costly therapy often fails to completely clear the infection and is associated with adverse side effects. Recent anti-HCV therapies are interferon-free direct-acting antiviral (DAA) regimens for HCV, including simeprevir, sofosbuvir, and ledipasvir, which have effects on non-structural proteins. DAA regimens have several advantages, such as specifically targeting HCV viral replication, accompanied by very high sustained virological response rates and lower side effects like flu-like syndrome. These facts plus the fact that most HCV cases progress to chronic infection suggest the potential need for an efficient HCV vaccine. Different innovative methods, including methods based on peptide, recombinant protein, DNA, vector-based, and virus-like particles, have been introduced for the development of HCV vaccines. An extensive number of studies have been published on these vaccines, and some vaccines were even tested in clinical trials. In the current review, progress in the development of preventive and therapeutic vaccines against the HCV is reviewed in the context of peptide vaccines, recombinant protein vaccines, HCV-like particle, DNA vaccines and viral vectors expressing HCV genes. © 2015 Baishideng Publishing Group Inc. All rights reserved.

Item Type: Article
Additional Information: Cited By :22 Export Date: 16 February 2020 CODEN: WJGAF Correspondence Address: Meshkat, Z.; Antimicrobial Resistance Research Center, Faculty of Medicine, Mashhad University of Medical SciencesIran; email: meshkatz@mums.ac.ir
Uncontrolled Keywords: Hepatitis C virus Hepatitis C virus infection Preventive vaccine Therapeutic vaccine DNA vaccine hepatitis C vaccine peptide vaccine recombinant protein recombinant vaccine virus vector hepatitis vaccine Article cellular immunity controlled clinical trial (topic) gene expression genetic variability hepatitis C human humoral immunity immune evasion immune response infection prevention innate immunity nonhuman phase 1 clinical trial (topic) phase 2 clinical trial (topic) preventive medicine randomized controlled trial (topic) vaccine production viral genetics virology virus gene virus like agent animal drug development genetics genotype Hepacivirus host pathogen interaction immunization immunology pathogenicity phenotype procedures Animals Drug Discovery Host-Pathogen Interactions Humans Viral Hepatitis Vaccines
Subjects: WC Communicable Diseases
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib5 lib5
Date Deposited: 10 May 2020 16:46
Last Modified: 10 May 2020 16:46
URI: http://eprints.mums.ac.ir/id/eprint/18855

Actions (login required)

View Item View Item